Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Jan 20, 2016 at 8:40 AM EST

Has a Zafgen Turnaround Begun?

Despite facing setbacks recently, Zafgen pushed ahead and led the bulls early on Wednesday on news of positive results.

Chris Lange | Jan 19, 2016 at 11:20 AM EST

Johnson & Johnson Plans to Cut Roughly 3,000 Jobs in Medical Devices

Johnson & Johnson is looking to save some money over the next few years and as a result it is…

Chris Lange | Jan 19, 2016 at 9:15 AM EST

UnitedHealth Impresses Shareholders by Meeting Earnings

UnitedHealth Group released a better-than-expected fourth-quarter earnings report before the markets opened on Tuesday.

Chris Lange | Jan 16, 2016 at 10:20 AM EST

4 Top BioPharma Movers of the Past Week

These biotech companies stood out from the rest with big moves over the course of the past week.

Chris Lange | Jan 15, 2016 at 11:35 AM EST

The Unusual Merrill Lynch Upgrade of Gilead Sciences

Merrill Lynch sees some stabilization in the hepatitis C market in 2016 that might allow Gilead Sciences to stay above…

Chris Lange | Jan 15, 2016 at 10:05 AM EST

Why Sarepta Therapeutics Is Cratering

Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.

Lee Jackson | Jan 14, 2016 at 8:35 AM EST

3 Top Jefferies Biotech Stocks to Buy for 2016 With Huge Upside Potential

These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry…

Chris Lange | Jan 13, 2016 at 9:15 AM EST

Major Pharma Short Sellers Increase Bets

The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks…

Chris Lange | Jan 13, 2016 at 8:35 AM EST

Short Interest Remains Mixed for Major Biotechs

The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech…

Chris Lange | Jan 11, 2016 at 1:15 PM EST

Halozyme Therapeutics Sinks on Business Update

Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th…

Chris Lange | Jan 11, 2016 at 12:40 PM EST

Celgene Disappoints Investors by Meeting Estimates

Celgene Corp. (NASDAQ: CELG) sank in Monday's session after providing a business update that was largely in line with analyst…

Chris Lange | Jan 11, 2016 at 12:05 PM EST

Anavex Soars on Positive Alzheimer’s Results

Anavex Life Sciences was one of the stocks helping to prop up the market in Monday’s session.

Chris Lange | Jan 11, 2016 at 10:05 AM EST

Clearside Files for IPO

Clearside Biomedical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Lee Jackson | Jan 11, 2016 at 9:50 AM EST

3 Biotech Stocks With 2016 Phase 3 Data That Could Have Huge Upside Potential

A new RBC report focuses on top biotech stocks with key data readouts coming in 2016. These three seem to…

Chris Lange | Jan 11, 2016 at 9:05 AM EST

Is Thermo Fisher Overpaying for Affymetrix?

Affymetrix was absolutely soaring early on Monday on word that it will be acquired. Thermo Fisher Scientific is the buyer.

1 … 227 228 229 230 231 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Has a Zafgen Turnaround Begun?

Johnson & Johnson Plans to Cut Roughly 3,000 Jobs in Medical Devices

UnitedHealth Impresses Shareholders by Meeting Earnings

4 Top BioPharma Movers of the Past Week

The Unusual Merrill Lynch Upgrade of Gilead Sciences

Why Sarepta Therapeutics Is Cratering

3 Top Jefferies Biotech Stocks to Buy for 2016 With Huge Upside Potential

Major Pharma Short Sellers Increase Bets

Short Interest Remains Mixed for Major Biotechs

Halozyme Therapeutics Sinks on Business Update

Celgene Disappoints Investors by Meeting Estimates

Anavex Soars on Positive Alzheimer’s Results

Clearside Files for IPO

3 Biotech Stocks With 2016 Phase 3 Data That Could Have Huge Upside Potential

Is Thermo Fisher Overpaying for Affymetrix?

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Health and Healthcare Articles

All Health and Healthcare Articles

Has a Zafgen Turnaround Begun?

Johnson & Johnson Plans to Cut Roughly 3,000 Jobs in Medical Devices

UnitedHealth Impresses Shareholders by Meeting Earnings

4 Top BioPharma Movers of the Past Week

The Unusual Merrill Lynch Upgrade of Gilead Sciences

Why Sarepta Therapeutics Is Cratering

3 Top Jefferies Biotech Stocks to Buy for 2016 With Huge Upside Potential

Major Pharma Short Sellers Increase Bets

Short Interest Remains Mixed for Major Biotechs

Halozyme Therapeutics Sinks on Business Update

Celgene Disappoints Investors by Meeting Estimates

Anavex Soars on Positive Alzheimer’s Results

Clearside Files for IPO

3 Biotech Stocks With 2016 Phase 3 Data That Could Have Huge Upside Potential

Is Thermo Fisher Overpaying for Affymetrix?

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation